Jessica L. Geiger

Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis

We previously reported the results of a multicenter phase II trial (ClinicalTrials.gov identifier: NCT04154943 ) of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous cell carcinoma (CSCC), in which the pathologic complete response (pCR) rate was 51%. At the 1...

Tumor-informed molecular residual disease in resected mucosal and cutaneous squamous cell carcinomas of the head and neck

Abstract Patients with resected mucosal (HNSCC) or cutaneous (cSCC) squamous carcinomas of the head and neck undergo adjuvant therapy based on clinicopathologic prognosticators. Most patients are overtreated or undertreated, with substantial morbidity from locoregional recurrence...